JOEL D. MEYERS, M.D.; JEANNE LESZCZYNSKI, Dr.P.H.; JOHN A. ZAIA, M.D.; NANCY FLOURNOY, Ph.D.; BARBARA NEWTON, R.N.; DAVID R. SNYDMAN, M.D.; GEORGE G. WRIGHT, Ph.D.; MYRON J. LEVIN, M.D.; E. DONNALL THOMAS, M.D.
In an effort to prevent cytomegalovirus infection among seronegative patients having marrow transplants, a globulin with high antibody levels against cytomegalovirus was given before and for 11 weeks after transplantation in a randomized trial. Among 36 patients who received no prophylactic granulocyte transfusions, globulin recipients had significantly fewer infections than controls (2 of 17 versus 8 of 19, p = 0.05 by Fisher's exact test and p = 0.03 by Mantel-Cox test). Conversely, infection rates were high and unchanged by globulin use among patients who received granulocytes from seropositive donors (7 of 8 recipients versus 6 of 7 controls). The lack of effect of the globulin among patients receiving transfusions of granulocytes from seropositive donors may suggest that the dose of antibody was insufficient or that antibody is ineffective against virus transmitted in granulocytes. We conclude that cytomegalovirus infection can be prevented by immunoprophylaxis in seronegative patients having marrow transplants who are not given granulocyte transfusions.
MEYERS JD, LESZCZYNSKI J, ZAIA JA, et al. Prevention of Cytomegalovirus Infection by Cytomegalovirus Immune Globulin After Marrow Transplantation. Ann Intern Med. 1983;98:442–446. doi: 10.7326/0003-4819-98-4-442
Download citation file:
Published: Ann Intern Med. 1983;98(4):442-446.
Hematology/Oncology, Infectious Disease.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use